EMA
The European Medicines Agency (EMA) is a decentralised agency of the European Union, located in London. The Agency is responsible for the scientific evaluation of medicines developed by pharmaceutical companies for use in the European Union. It began operating in 1995.
Business & Industry
- AstraZeneca advances response to global COVID-19 challenge as it receives first commitments for Oxford's potential new vaccine
- Pfizer and BioNTech dose first participants in the U.S. as part of global COVID-19 mRNA vaccine development program
- Roche's COVID-19 antibody test receives FDA Emergency Use Authorization and is available in markets accepting the CE mark
- AstraZeneca and Oxford University announce landmark agreement for COVID-19 vaccine
- Gilead announces results from Phase 3 trial of investigational antiviral remdesivir in patients with severe COVID-19
Research & Development
- Preventing 'cytokine storm' may ease severe COVID-19 symptoms
- Official COVID-19 deaths underestimate the full impact of the pandemic
- Local climate unlikely to drive the early COVID-19 pandemic
- Researchers urge clinical trial of blood pressure drug to prevent complication of COVID-19
- Antibody neutralizes SARS and COVID-19 coronaviruses
- Early indicators of vaccine efficacy
- Arthritis drug may improve respiratory function in some patients with severe COVID-19
Conferences & Events
- Pre-filled Syringes San Francisco Conference 2020
- Oligonucleotide Therapeutics and Delivery Conference 2020
- Pre-Filled Syringes West Coast 2021
- Pre-Filled Syringes East Coast Conference 2020
- SMi's 4th Annual Pharmaceutical Microbiology West Coast
- SMi's 20th Annual Pain Therapeutics Conference 2020
- SMi's 3rd Annual Pharmaceutical Microbiology East Coast
Regulatory Affairs
- Global regulators commit to cooperate on observational research in the context of COVID-19
- FDA takes new actions to accelerate development of novel prevention, treatment options for COVID-19
- FDA Issues Emergency Use Authorization for Potential COVID-19 Treatment
- FDA reiterates importance of close patient supervision for 'off-label' use of antimalarial drugs
- FDA encourages recovered patients to donate plasma for development of blood-related therapies